248 related articles for article (PubMed ID: 33200682)
1. Pharmacophore based virtual screening, molecular docking and molecular dynamic simulation studies for finding ROS1 kinase inhibitors as potential drug molecules.
Vanajothi R; Vedagiri H; Al-Ansari MM; Al-Humaid LA; Kumpati P
J Biomol Struct Dyn; 2022 May; 40(8):3385-3399. PubMed ID: 33200682
[TBL] [Abstract][Full Text] [Related]
2. Structure-guided identification of potent inhibitors of ROS1 kinase for therapeutic development against non-small cell lung cancer.
Khan MS; Altwaijry N; Al-Bagmi MS; Alafaleq NO; Alokail MS; Shahwan M; Shamsi A
J Biomol Struct Dyn; 2024 May; 42(8):3837-3847. PubMed ID: 37254309
[TBL] [Abstract][Full Text] [Related]
3. Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis.
Pathak D; Chadha N; Silakari O
J Mol Graph Model; 2016 Nov; 70():85-93. PubMed ID: 27693947
[TBL] [Abstract][Full Text] [Related]
4. Structural Insights into the Molecular Design of ROS1 Inhibitor for the Treatment of Non-Small Cell Lung Cancer (NSCLC).
Adhikary R; Khandelwal R; Hussain T; Nayarisseri A; Singh SK
Curr Comput Aided Drug Des; 2021; 17(3):387-401. PubMed ID: 32364080
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
6. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
Wu X; Wang Y; Wan S; Zhang J
J Biomol Struct Dyn; 2018 Sep; 36(12):3106-3113. PubMed ID: 28893136
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
8. Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy.
Liu S; Yang H; Jiang Y; Zhang T; Yan R; Zhang J
Future Med Chem; 2018 Jul; 10(14):1705-1720. PubMed ID: 29961337
[TBL] [Abstract][Full Text] [Related]
9. Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK.
Tian Y; Yu Y; Shen Y; Wan H; Chang S; Zhang T; Wan S; Zhang J
J Chem Inf Model; 2017 Apr; 57(4):977-987. PubMed ID: 28318251
[TBL] [Abstract][Full Text] [Related]
10. Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors.
Park BS; Al-Sanea MM; Abdelazem AZ; Park HM; Roh EJ; Park HM; Yoo KH; Sim T; Tae JS; Lee SH
Bioorg Med Chem; 2014 Aug; 22(15):3871-8. PubMed ID: 24997577
[TBL] [Abstract][Full Text] [Related]
11. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
[TBL] [Abstract][Full Text] [Related]
12. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC.
Pathak D; Choudhary S; Singh PK; Singh M; Chadha N; Silakari O
Mol Divers; 2021 May; 25(2):1091-1102. PubMed ID: 32002714
[TBL] [Abstract][Full Text] [Related]
14. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
Dziadziuszko R; Le AT; Wrona A; Jassem J; Camidge DR; Varella-Garcia M; Aisner DL; Doebele RC
J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
[TBL] [Abstract][Full Text] [Related]
15. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
Roys A; Chang X; Liu Y; Xu X; Wu Y; Zuo D
Cancer Chemother Pharmacol; 2019 Oct; 84(4):679-688. PubMed ID: 31256210
[TBL] [Abstract][Full Text] [Related]
16. Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors.
Xiao J; Zhang S; Luo M; Zou Y; Zhang Y; Lai Y
J Mol Graph Model; 2015 Jul; 60():142-54. PubMed ID: 26043662
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
20. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
